NEFL and myeloid sarcoma: Thus, plasma and serum NfL levels have been studied as a marker for conditions such as AD (Mattsson et al., 2017), cSVD (Egle et al., 2021; Gattringer et al., 2017), MS (Bittner et al., 2021), and primary progressive aphasia (Steinacker et al., 2017).